The p53 tumor suppressor is a critical regulator of tissue homeostasis, and its inactivation at the gene or protein level confers cellular properties conducive for oncogenesis and cancer progression. Furthermore, p53 inactivation has been associated with resistance to therapy. Indeed, the p53 response is deficient in 450% of cancers mainly through gene mutation. 1 In contrast to other solid tumors and carcinomas, TP53 mutations are rare in multiple myeloma (MM), a malignancy characterized by clonal plasma cells secreting monoclonal immunoglobulin. 2 Previous studies of TP53 mutations in MM were hampered by clinical heterogeneity in the study cohorts and the relatively small sample size (all with o100 patients). These studies reported a prevalence of TP53 mutation ranging from 0 to 20%. 2 However, it is not always obvious whether the study cohorts consist of newly diagnosed or relapsed patients. This is important as the prevalence of TP53 mutations increases with more advance disease (even this is not clearly defined and seemed to include Durie-Salmon stage III and plasma cell leukemia) and is very prevalent in HMCLs. 2 Furthermore, these studies generally limit their investigation to exons 5-9, whereas several studies in other cancers have shown that mutations can occur in other exons. 1 At present, the prognostic importance of TP53 mutations in myeloma is unknown.
In this study, we comprehensively define the prevalence of TP53 mutations in newly diagnosed myeloma patients by screening genomic DNA from unsorted whole bone marrow from a large cohort of patients entered into an Eastern Cooperative Oncology Group clinical trial E9486/E9487 (n ¼ 561) using conformation sensitive gel electrophoresis (CSGE). A total of 268 patients, based on sample availability, were included in our current study. These patients had extensive follow-up information with median follow-up of survivors 4.8 years and only 4.5% (n ¼ 25) of the cohort alive at the time of our analysis, resulting in negligible censoring. Fluorescent in situ hybridization (FISH) studies using the cytoplasmic immunoglobulin-FISH technique in this cohort of patients has been previously reported. 3 Polymerase chain reaction primers were designed to amplify 11 DNA fragments from exon 1 to 11 (exon 1: CCA TGT GCT  CAA GAC TGG C, CGA GCT GAA AAT ACA CGG AG; exon 2:  CAG GAG TGC TTG GGT TGT, CCC ACA GGT CTC TGC TAG  G; exon 3: CTG TGG GAA GCG AAA AT, GAT GGG TGA AAA  GAG CAG TCA; exon 4: GGG CTG AGG ACC TGG T, ACA  GGA AGC CTA AGG GTG AAG; exon 5: TTG CTG CCG TGT  TCC A, CAA CCA GCC CTG TCG TCT CT; exon 6: GGC TGG  AGA GAC GAC AGG G, ATC TCA TGG GGT TAT AGG GAG;  exon 7: TTG CCA CAG GTC TCC C, ATG GAA GAA ATC GGT  AAG AG; exon 8: TTT AAA TGG GAC AGG TAG GAC, CTT  ACC TCG CTT AGT GCT; exon 9: GGG AGC ACT AAG CGA GGT A, CAA CCA GGA GCC ATT GTC TTT; exon 10: TTG CTT TTG TAC CGT CAT AA, ACA GCT GCC TTT GAC CAT; exon 11: GCA CAG ACC CTC TCA CTC ATG TGA, AGA CCC AAA ACC CAA AAT G). The primers were optimized and grouped into three multiplex reactions. These groups had to be compatible according to primer length, MgCl 2 concentration and annealing temperature. Multiplex one contained exons 4, 7, 8 and 10; multiplex two contained exons 1, 3, 5 and 9; and multiplex three contained exons 2, 6, 7 and 11. The radiolabeled amplicons were run through 15% mild denaturing 0.4 mm polyacrylamide gel for 4 h at 40 W. The gel was dried and placed on a photoimager screen for analysis. Abnormal banding patterns were subsequently directly sequenced.
It appears that TP53 mutations are relatively rare in newly diagnosed patients as only nine of the 268 samples (3%) tested were positive for mutations. The actual prevalence may be slightly higher if one considers the sensitivity of CSGE (10%) and the fact that non-purified bone marrow samples are used (bone marrow samples were all collected before the availability of practical CD138 þ cell sorting). However, the median plasma cell infiltration of the cohort is 40% (range 20-95%) with 70% of patients having more than 30% of plasma cells in the bone marrow. Only three of the mutations are point mutations, and majority resulted in premature termination and a predicted truncated protein product ( Table 1) . Seven of the nine mutations occurred in the DNA-binding domain, where the majority of reported TP53 mutations occur. However, we did not see any mutations in codons 175, 245, 248, 249, 273 and 282 that accounts for 28% of all TP53 mutations in cancers. 1 In addition, we found several mutations outside exons 5-9 (all previous studies only examined exons, 5-9). None of the mutations are known polymorphism and all of them are predicted to alter protein structure and function. Therefore, the spectrum of TP53 mutations is broad and not typical of other malignancies.
We also examined the association between the presence of TP53 mutations and other clinical features and common genetic abnormalities using the Fisher's exact test. The presence of TP53 mutations was associated with presence of soft tissue plasmacytoma (37 versus 7%, P ¼ 0.018). Unlike previous studies that found TP53 mutation to be more common in advance stage MM, we could not confirm this because the distribution of International Staging System (ISS) stage is relatively even, although clearly the total number of patients with an abnormality is quite small to draw firm conclusions. As our analysis was conducted in newly diagnosed and pretreatment samples, it provides a better baseline for examining the relation between TP53 mutation and disease stage.
The presence of TP53 mutations was significantly associated with 17p13 deletions as five of the nine patients (56%) with mutation also had 17p13 hemizygous loss (versus 10%, P ¼ 0.01). This is consistent with previous observations in other malignancies that many tumors that harbor TP53 mutations also show loss of heterozygosity. 1 In those patients with only 17p13 hemizygous loss, it would be important to assess how the p53 pathway is affected and whether the other allele of p53 is suppressed by other means such as epigenetic mechanisms. These studies are currently being conducted in our laboratory. Patients with TP53 mutations were also enriched for primary translocations, such as t(11;14), t(4;14) and t(14;16) (67 versus 24%, P ¼ 0.014). In contrast, there was no association with D13 or hyperdiploid status.
We also report for the first time the prognostic significance of TP53 mutations. The presence of TP53 mutations was associated with very poor survival of only one and a half years ( Figure 1) . We have previously reported the short survival associated with 17p13 deletions in this cohort of patients. 3 We did not report on the difference in outcome for those with 17p13 deletions and TP53 mutation versus those with 17p13 deletions and no TP53 mutation separately as the total number of patients in each category is small. It is therefore unclear if the negative prognostic association of 17p13 deletions is solely due to its association with TP53 mutations or whether it also confers a more aggressive disease phenotype on its own.
As TP53 mutation and 17p13 deletion affect the same genetic pathway, we decided to group them together for further analysis of their prognostic impact. Together they afflict 13% of newly diagnosed patients, almost equivalent to the prevalence of t(4;14) or t(11;14). 2 In a multiple regression Cox proportional hazard analysis with other known prognostic factors including the recently devised ISS, 4 PCLI, plasmablastic morphology, t(4;14) or t(14;16), D13 status and 17p13 deletion in patients with complete information (n ¼ 202), the presence of TP53 mutation or deletion emerged as an independent prognostic factor together with ISS stage 3, PCLI41 and t(4;14) or t(14;16) ( Table 2) . As both the presence of TP53 mutations or deletions were associated with translocation group status, we further analyzed the survival of the t(4;14) and t(14;16) subset according to their p53 status (mutation or deletion). In this subset of 34 patients, those with TP53 abnormalities (n ¼ 9) had significantly shorter survival with a median survival of 16.7 months (95% CI 4.3-22.0 months) versus 29.2 months (95% CI 24.7-48.7 months, log-rank Po0.001). Although this is exploratory, this suggests that even among patients with high-risk cytogenetic features, TP53 mutation or deletion is likely a progression event with impact on the actual outcome of patients. Therefore, the presence of TP53 abnormalities is an independent prognostic factor and clearly identifies a high-risk patient cohort.
Importantly, the presence of TP53 abnormalities identifies a high-risk patient cohort that could potentially be specifically targeted therapeutically. Onyx-015, 5 a permitting viral replication exclusively in cells with defective p53 and induction of tumor specific cell lysis, or a gene therapy approach using ad5CMV-p53 (INGN 201; ADVEXIN; Introgen Therapeutics Inc., Houston, TX, USA), 6 a replication defective adenoviral construct containing the wild-type TP53 gene that delivers a normal TP53 gene into p53 defective tumor cells thereby restoring p53 function have already shown promise in early clinical studies. 7, 8 In conclusion, although TP53 mutations are relatively rare in newly diagnosed myeloma patients, their presence confers significantly worse overall survival compared to patients without mutation. The presence of TP53 abnormalities (mutations or deletions) is seen in 13% of newly diagnosed myeloma patients and is an independent poor prognostic factor. The knowledge of the genetic abnormality that identifies this high-risk cohort may be exploited therapeutically by specifically targeting cells with TP53 abnormalities. 
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Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6/RUNX1-rearranged childhood acute lymphoblastic leukemia The term '11q23 abnormalities' was originally used to describe various morphological changes of the terminal part of chromosome 11q that are evident on the cytogenetic level only. However, following the adoption of this term by molecular biologists and clinicians, it is now used to denote all genetic alterations that are encountered within this region regardless of the method of their ascertainment. Chromosome band 11q23 is the site of the mixed lineage leukemia (MLL) gene that is most often disrupted in 11q23 abnormalities of various hematological neoplasms. Although 11q23/MLL aberrations are usually recognized as being reciprocal on the chromosomal level, few could nevertheless be interpreted as an unbalanced rearrangement or deletion. Thus, apart from its value to detect virtually all MLLinvolving rearrangements on a single-cell level, dual-color fluorescence in situ hybridization (FISH) analysis with 3 0 and 5 0 MLL split-apart probes is also very helpful to discover cases with either 3 0 MLL or even complete MLL deletions. 1 Genetic abnormalities involving the 11q23/MLL region account for about 5-10% of childhood acute lymphoblastic leukemia (ALL). Patients with an 11q23 deletion in which an entire MLL allele may or may not be eliminated account for approximately 20% of the 11q23-rearranged cases. 2, 3 Although there are limited data on the biological and clinical characteristics as well as the prognosis of a del(11)(q23) in pediatric ALL, a few previous studies showed that this abnormality was commonly associated with low-risk features at presentation and survival rates of approximately 75%. 2, 3 The detection of several cases with such 11q deletions during our screening program for secondary genetic abnormalities in ETV/RUNX1 þ B-cell precursor (BCP) ALL led us assess the incidence as well as the clinical, laboratory and biological features of 11q23-deleted cases in a population-based cohort of consecutively registered BCP ALL patients. 5 From 1999 onward, infants with ALL were enrolled in trial INTERFANT-A 1999 (n ¼ 8). ALL was diagnosed according to standard morphological, cytochemical and immunophenotypic criteria. All cases were reviewed by the National Study Center in Vienna and treated after obtaining informed consent from the patients, patient's parents or legal guardians. Out of the 948 patients, 824 (87%) had a B-lineage ALL and 122 (13%) a T-lineage ALL. Two patients had an acute undifferentiated leukemia with FAB L1/L2 morphology. Cytogenetic analyses were performed centrally and results were classified according to the guidelines of the International System for Human Cytogenetic Nomenclature (ISCN) 1995. ETV6/ RUNX1 and MLL FISH analyses were also carried out centrally according to standard procedures. 1, 4 Among the 673/824 (82%) patients with B-lineage ALL who had cytogenetic data available, we identified 27 (4%) cases with 11q23 abnormalities (Table 1) . They included 12 patients (44%) with a t(4;11)(q21;q23), four patients (15%) with a t(11;19)(q23;p13), eight patients (30%) with a del(11)(q23) and one patient each with a t(9;11)(p22;q23), a t(1;11)(q32;q23) and a t(1;9;11;19)(q21;p13;q12q23;p13). All eight patients with a del(11)(q23) showed a good prednisone response with less than 1000/ml blast cells in peripheral blood on day 8 after a 7-day treatment with prednisone and one intrathecal dose of methotrexate on day 1. Bone marrow (BM) at day 15 was evaluated in seven of the eight patients, demonstrating M1 BM in three and M2 BM in four cases. All patients achieved a complete remission by day 33.
The eight patients with a del(11)(q23) were found to be significantly associated with an age of 1-10 years (P ¼ 0.002), low white blood cell (WBC) counts (Po0.001) and a CD10 þ BCP immunophenotype (Po0.001), as compared to the 17 patients with 11q23/MLL translocations. The two patients with a t(1;11) and a t(1;9;11;19) had not been included in this analysis as FISH analysis disclosed the lack of a MLL-involving translocation. Out of the eight patients with a del(11)(q23), only one suffered from a relapse and that occurred 4.13 years after primary diagnosis and was localized to the right ovary only. The patient is now in continuous remission after secondline chemotherapy. Another patient developed a secondary MLL-rearranged AML 4.50 years after ALL diagnosis. This patient was rescued with a high-dose regimen followed by bone marrow transplantation from a matched-unrelated donor.
After a median follow-up of 8.15 years (range 0.83-17.67 years), the 8-year probabilities of event-free and relapse-free survival were 69719 and 86713% for the eight patients with a del(11)(q23). In comparison, both the 8-year probability of
